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http://dx.doi.org/10.1016/j.ccr.2014.05.016SUMMARYMacrophage infiltration has been identified as an independent poor prognostic factor in several cancer types.
The major survival factor for these macrophages is macrophage colony-stimulating factor 1 (CSF-1). We
generated a monoclonal antibody (RG7155) that inhibits CSF-1 receptor (CSF-1R) activation. In vitro
RG7155 treatment results in cell death of CSF-1-differentiated macrophages. In animal models, CSF-1R in-
hibition strongly reduces F4/80+ tumor-associated macrophages accompanied by an increase of the CD8+/
CD4+ T cell ratio. Administration of RG7155 to patients led to striking reductions of CSF-1R+CD163+ macro-
phages in tumor tissues, which translated into clinical objective responses in diffuse-type giant cell tumor
(Dt-GCT) patients.INTRODUCTION
Colony-stimulating factor 1 (CSF-1) and its receptor, CSF-1R,
regulate the migration, differentiation, and survival of macro-
phages and their precursors (Hume and MacDonald 2012; Chitu
and Stanley 2006). CSF-1R is a member of the receptor proteinSignificance
Preclinical data indicate that tumor-associated macrophages
represent key orchestrators of various tumor-promoting proces
that treatment with an anti-CSF-1R antibody (RG7155) deple
various tumor types. Moreover, in Dt-GCT patients, a neo
RG7155-induced reduction of CSF-1R+ mononuclear cells pr
option other than surgery, which is associated with a high lik
for exploring combination therapies especially in those tumor
846 Cancer Cell 25, 846–859, June 16, 2014 ª2014 Elsevier Inc.tyrosine kinase (rPTK) family of growth factor receptors, which
includes several known proto-oncogenes. Themolecular pathol-
ogy of the diffuse-type giant cell tumor (Dt-GCT; formerly known
as pigmented villonodular synovitis [PVNS or Dt-PVNS]), a rare
proliferative disease affecting large joints, vividly demonstrates
the effects of deregulated CSF-1 production. In the majority of(TAMs) represent an attractive therapeutic target as they
ses, such as escape of immune surveillance. Here, we report
tes TAMs from the tumor tissue of cancer patients across
plastic disorder characterized by CSF-1 overexpression,
ovided significant clinical benefits and offers a therapeutic
elihood of relapse. Furthermore, our work forms the basis
entities in which TAMs contribute to tumor pathogenesis.
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gene encoding CSF-1 result in overexpression of this cytokine
by cells within the synovial lining (West et al., 2006). This leads
to massive recruitment of CSF-1R-expressing cells, mainly
nonmalignant mononuclear and multinucleated cells that form
the bulk tumorous mass (Cupp et al., 2007; West et al., 2006).
Marginal excision or complete synovectomy remain the treat-
ments of choice (Ravi et al., 2011) for Dt-GCT, but the disorder
sometimes necessitates mutilating surgery due to locally
destructive and recurring tumor growth. Another investigational
approach for treating Dt-GCT patients exploits the CSF-1R-
targeting component of the tyrosine kinase inhibitor imatinib
mesylate (Gleevec), thus suggesting that this receptor repre-
sents an attractive target for development of cancer therapies
(Cassier et al., 2012; Blay et al., 2008).
In solid tumors, such as those in breast and pancreatic cancer,
infiltrating CD68+ or CD163+ tumor-associated macrophages
(TAMs) correlate with poor outcome (DeNardo et al., 2011; Kur-
ahara et al., 2011; Shabo et al., 2008). The tumor-promoting
function of TAMs is based on their capacity to secrete proangio-
genic and growth factors, as well as to potently suppress T cell
effector function by releasing immunosuppressive cytokines
and affecting their metabolism (Wynn et al., 2013; Biswas and
Mantovani 2010; Gordon and Martinez 2010; Hoves et al.,
2006). Macrophages exerting these protumorigenic functions
are also termed M2-type macrophages, in contrast to the antitu-
morigenic M1 subtype (Mantovani et al., 2002).
Here, we investigate the effect of blocking CSF-1R signaling
by a humanized anti-CSF-1R antibody (RG7155) and the result-
ing effect on TAMs in vitro, in in vivo animal models, and in
RG7155-treated Dt-GCT patients and patients with various other
malignancies.
RESULTS
Antibody RG7155 Blocks CSF-1R Dimerization
We generated and characterized RG7155, a humanized anti-
human CSF-1R immunoglobulin G1 (IgG1) monoclonal anti-
body that binds to human and cynomolgus CSF-1R with high
affinity (KD = 0.2 nM, as determined by surface plasmon reso-
nance [SPR]; Figure 1A). The binding epitope and the mode of
action of RG7155 was characterized using the crystal structure
of the full-length CSF-1R extracellular domain (ECD) bound to
the RG7155 Fab fragment in a 1:1 ratio (Figure 1B and Table
S1). In the structure, the ligand binding domains D1–D3 of
CSF-1R (Ma et al., 2012) are assembled into a helical-like
arrangement, in contrast to the planar surface of the receptor
dimerization interface formed by domains D4 and D5.
RG7155 blocks the receptor dimerization interface with its
epitope being located within D4 and D5 (Figures 1C and 1D).
Previously, it has been shown for the homologous type III re-
ceptor tyrosine kinase (RTK) c-Kit that homotypic D4-D4 con-
tacts between a strictly conserved Arg-Glu residue pair are
essential for formation of the receptor dimer interface (Yuzawa
et al., 2007). In our structure, the corresponding residues
D4Arg370 and D4Glu375 form salt bridge contacts with Asp98
and Arg100 of the heavy chain CDR3 of RG7155, thereby pre-
venting lateral receptor contacts (Figure 1C). Mutation analysis
of the CSF-1R ECD confirmed that binding of RG7155 wasabolished in constructs lacking D4 or D5 as determined by
SPR (Figure 1E).
High-affinity binding of dimeric CSF-1 to CSF-1R requires re-
ceptor dimerization (Verstraete and Savvides 2012; Elegheert
et al., 2011). This cooperative formation of the ligand receptor
complex is inhibited by RG7155’s blocking the receptor dimer-
ization interface. As a consequence, the antibody inhibits bind-
ing of both CSF-1 and the other ligand, interleukin-34 (IL-34),
to CSF-1R in a competitive manner (Figure 1F). Additionally,
RG7155 blocks the transforming activity of a ligand-independent
CSF-1R mutant, resulting in significantly reduced cell viability of
NIH 3T3-CSF-1R L301S Y969F recombinant cells (Roussel et al.,
1990) (Figure S1A) and OCl-AML-5 (wild-type [WT] CSF-1R; Fig-
ure S1B). Other human type III RTKs such as c-Kit and platelet-
derived growth factor, or mouse CSF-1R, are not targeted by
RG7155 (data not shown), thus confirming the selectivity of
this antibody. Taking these data together, we conclude that
RG7155 is a selective CSF-1R receptor dimerization inhibitor
that blocks ligand-dependent and ligand-independent receptor
activation.
RG7155 Depletes CSF-1R+CD163+ Macrophages
In Vitro and In Vivo
Human macrophages were differentiated from monocytes
in vitro in the presence of either CSF-1 or granulocyte macro-
phage (GM)-CSF. CSF-1-differentiated macrophages were
characterized by the expression of CSF-1R and CD163, whereas
differentiation with GM-CSF resulted in CD80+MHC-IIhigh-ex-
pressing macrophages with undetectable CD163 and CSF-1R
(Figure 2A). This profile indicates an M2-like polarization of mac-
rophages in the presence of CSF-1 (Geissmann et al., 2010;
Martinez et al., 2008). RG7155 potently inhibited the viability of
CSF-1-differentiated macrophages with an IC50 of 0.3 nM by
inducing cell death (Figures 2B and S1C). Moreover, cross-titra-
tion of GM-CSF and CSF-1 revealed that addition of small
amounts of GM-CSF can protect macrophages from RG7155-
induced apoptosis (Figure 2B).
To mimic the physiologic concentrations of these two cyto-
kines in the tumor context, we investigated the effect of
RG7155 on macrophages (TC-Macs) differentiated with tumor-
conditioned media (TCM). Differentiation of TC-Macs suscepti-
ble to RG7155 was enabled by TCM with high CSF-1 and low
GM-CSF levels, in contrast to tumor cells secreting high concen-
trations of GM-CSF (Figure 2C). Furthermore, these TC-Macs
differentiated with high CSF-1 TCM displayed anM2-like pheno-
type characterized by a principal component analysis (PCA)
using the first, second, and third PC, based on 23 selected re-
ceptors, cytokines, chemokines, and growth factors (Figure S2).
TC-Macs differentiated with TCM containing high GM-CSF
showed a mixed M1/M2 phenotype. (Figure S2). Blockade of
both GM-CSF and CSF-1 signaling pathways resulted in cell
death of GM-CSF/CSF-1 polarized TC-Macs, while blockade
of each single cytokine did not (Figure 2D), confirming again
the dominating influence of GM-CSF on TC-Mac survival in the
presence of RG7155.
M2macrophages are also characterized by their ability to sup-
press T cell activation, which was confirmed for macrophages
susceptible to RG7155 in coculture assays with autologous
T cells: CSF-1-differentiated macrophages potently suppressedCancer Cell 25, 846–859, June 16, 2014 ª2014 Elsevier Inc. 847
Figure 1. RG7155 Binds to the Human CSF-1R Dimerization Interface
(A) SPR sensorgrams showing binding of a series of concentrations of human and cynomolgus CSF-1R ECD to RG7155 captured onto a Biacore sensor chip.
(B) Schematic representation (left) of theCSF-1R ECDdimer. Key residues Arg370 andGlu375most likely involved in dimerization in domain 4 are highlighted. The
overall structure of the CSF-1R ECD monomer complex with Fab fragment of RG7155 is shown in surface representation (right).
(C) Close-up view of the Fab fragment binding site. Important Fab fragment residues for interaction with domains 4 and 5 of the receptor are shown as sticks. The
surface patch in light gray resembles the receptor dimerization interface (based on an overlay with the c-KIT structure; Protein Data Bank [PDB] entry 2E9W) in
domains 4 and 5 of the CSF-1R ECD, which is blocked by RG7155.
(D) Mapping of the Fab (RG7155) epitope on the CSF-1R ECD domain 4 (surface in yellow) and domain 5 (surface in purple). Residues interacting with the Fab
(RG7155) HC (light blue), LC (cyan), or both HC and LC (dark blue) are labeled. Labels of residues involved in dimerization are shown in red.
(E) RG7155 requires both the D4 andD5 domains for binding. Full-length ECD/Fc (CSF-1R), dimeric CSF-1R delD4, D1-D4/Fc, andD1-D3/Fcwere amine coupled
onto a Biacore sensor chip, and binding of RG7155 and comparator monoclonal antibodies recognizing the ligand binding domain (Amgen and Imclone) or
domain D5 (Sherr et al., 1989) was determined at 5 nM. Signals were corrected for the level of immobilization and are reported for each monoclonal antibody
normalized to its binding of the full-length receptor = 100%.
(legend continued on next page)
Cancer Cell
Targeting Tumor-Associated Macrophages in Patients
848 Cancer Cell 25, 846–859, June 16, 2014 ª2014 Elsevier Inc.
Cancer Cell
Targeting Tumor-Associated Macrophages in PatientsCD4 and CD8 T cell proliferation induced by CD3/CD28 anti-
bodies (Figure 2E). In contrast, macrophages polarized toward
aM1phenotype by the TCM fromMDA-MB231 are least suscep-
tible to RG7155 mediated killing (Figure 2C). Indeed, these
TC-Macs were able to stimulate T cell proliferation (Figure 2F),
indicating that RG7155 efficiently eliminates immunosuppres-
sive M2-like macrophages.
The activity profile of RG7155 was tested in vivo using the
cross-reactive nonhuman primate Macaca fascicularis (Fig-
ure 1A). The pharmacokinetic (PK) and pharmacodynamic
(PD) profiles of RG7155 were assessed for various dose levels
in a single-dose and repeat-dose study. Two doses of 30 and
100 mg/kg were administered weekly for analysis of tissue-resi-
dent macrophages. The PK profile was nonlinear, suggesting a
target-mediated elimination pathway, pronounced at very low
doses and saturated at higher doses (Figure 3A). Plasma
CSF-1 concentrations increased at all tested doses immedi-
ately after RG7155 infusion and returned to baseline with
declining drug levels (Figure 3B). RG7155 mediated rapid elim-
ination of nonclassical CD14+CD16+, but not of classical
CD14+CD16, monocytes in peripheral blood of cynomolgus
monkeys. With increasing doses, more durable reduction of
nonclassical monocytes was observed. Of note, a strong
rebound effect on these monocytes occurred with decay of
RG7155 levels, most likely due to a stimulatory feedback
mechanism mediated by increased CSF-1 levels. The extent
and duration of the rebound phase of CD14+CD16+ monocytes
was dose dependent and transient (Figure 3C). RG7155 effi-
ciently reduced CSF-1R+ and CD68+163+ macrophages in the
liver (Kupffer cells) and colon of cynomologus monkeys. How-
ever, reduction of alveolar macrophages in the lung was rather
minor (Figure 3D).
Mouse CSF-1R Inhibition Results in Depletion of TAMs
and a Shift toward Higher CD8/CD4 T Cell Ratio
Since RG7155 does not cross-react with mouse CSF-1R (data
not shown), we generated a chimeric mouse IgG1 antagonistic
antibody (2G2) that binds to mouse CSF-1R with high affinity
(KD = 0.2 nM; Figure S3A). This antibody enables specific and
long-term CSF-1R inhibition in immune-competent mice.
Antibody 2G2 reduces survival of CSF-1-dependent murine
M-NFS-60 cells (Nakoinz et al., 1990), confirming its bioactivity
(Figure S3B). Both MC38 colorectal adenocarcinoma and
MCA1 fibrosarcoma represent tumor models that are dominated
by TAMs (Figures 4A and S3D). Flow-cytometric analysis of
MC38 tumor-associated immune cells revealed significant
reduction in TAMs (Figures 4A and S3F), accompanied by a rela-
tive increase of other types of immune cells including Ly6Ghigh
neutrophils, natural killer (NK) cells, and both CD4+ and CD8+
T cells (Figures 4A, 4B, S3F, and S3G). Importantly, tumors
recovered from 2G2 antibody-treated mice showed a pro-
nounced increase of CD8+ compared with CD4+ T cells, resulting
in a positive shift of the CD8 to CD4 ratio toward cytotoxic
effector T cells (Figure 4B). This changed ratio was associated(F) Binding of RG7155 to CSF-1R is competitive with ligand binding. Binding o
presence of increasing concentrations of CSF-1 or IL-34. The amount of free recep
inhibition of the maximal signal.
See also Figure S1 and Table S1.with a decrease in FoxP3+ T regulatory cells, which represent
the tumor-promoting subset of the CD4 T cell population (Fig-
ure 4C). These findings suggest that aside from the strong reduc-
tion of TAMs in the tumor infiltrate, other immune effector cells
are indirectly influenced by CSF-1R blockade.
The direct functional relationship between TAMs isolated from
MC38 tumors and T cells was investigated in coculture experi-
ments. TAMs markedly suppressed the in vitro expansion of
CD3/CD28-activated CD8+ T cells in a dose-dependent fashion
(Figure 4D). Hence, TAMs not only affect the frequency of T cells,
but also their functional activity. In both MC38 and MCA1 tumor
models, we observed that in vivo administration of 2G2 antibody
caused a delay in tumor growth (Figures 4E and S3C) associated
to a dramatic reduction of TAMs that contribute to the tumorous
mass (Figures 4A and S3D). Furthermore, 2G2 therapy reduced
the number of spontaneously developed metastases in the
MCA1 model (Figure S3E).
RG7155 Treatment Results in Marked Clinical Benefit
for Patients with Diffuse-Type Giant Cell Tumors
A phase 1 clinical trial was initiated with RG7155 that included
patients suffering from Dt-GCT. Eligible patients were treated
every 2 weeks by intravenous infusion and monitored by
(18F)-fluorodeoxy-glucose-positron emission tomography
(FDG-PET) and tumor biopsies at baseline and on treatment af-
ter two administrations of RG7155 (at 4 weeks of treatment).
Concurrently, whole blood was taken to investigate RG7155
infusion-related PK and PD effects (Figure 5A). Clinical activity
was demonstrated by high metabolic response rate based on
FDG-PET and objective clinical responses according to RE-
CIST 1.1 accompanied by significant symptomatic improve-
ment in all Dt-GCT patients as early as 4 weeks after treatment
initiation. All seven evaluable patients showed partial metabolic
response in FDG-PET imaging (according to the European Or-
ganization for Research and Treatment of Cancer, EORTC;
Young et al., 1999), with two patients approaching a complete
metabolic response. Five of the seven patients went on to
achieve partial responses (RECIST) at the first assessment
(Figure 5B).
The FDG-PET and magnetic resonance imaging (MRI) im-
ages of a 19-year-old female patient with recurring, nonresect-
able Dt-GCT of the right ankle clearly confirmed the disaggre-
gation of the tumorous mass by RG7155 treatment
(Figure 5C). Clinical activity correlated with a significant reduc-
tion of CD68+/CD163+ macrophages and of CSF-1R+ cells in
matching tumor biopsies (Figure 5D). The analysis of mono-
cytes in the peripheral blood of this patient revealed rapid
and sustained elimination of nonclassical CD14+CD16+ mono-
cytes between 5 and 96 hr after RG7155 infusion. Classical
CD14+CD16 monocytes did not show a sustained alteration
(Figure 5E). Accordingly, CSF-1R expression was significantly
increased on nonclassical monocytes compared to classical
activated and intermediate monocytes analyzed from healthy
donors (Figure 5F).f CSF-1R/Fc (4 nM) to sensor-chip-captured RG7155 was determined in the
tor boundwas calculated using a calibration curve and depicted as the percent
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Figure 2. RG7155 Induces Cell Death of In Vitro-Differentiated Human M2-like, but Not M1-like, Macrophages
(A) Surface marker profile of GM-CSF (M1)- or CSF-1 (M2)-differentiated macrophages was assessed by flow cytometry. The given numbers indicate the mean
ratio fluorescence intensity (MRFI ± SD; nR 5) calculated from the antigen’s MFI (empty profiles) relative to the matching isotype (filled profiles).
(B) Macrophages were differentiated using different ratios of CSF-1 and/or GM-CSF in presence of RG7155. Cell viability was determined at day 7 using CellTiter-
Glo. Data are pooled from four independent experiments and are shown as means ± SD (each sample run in triplicate; pairwise comparisons by Tukey-Kramer
test; p < 0.0001).
(C) RG7155 inhibits monocyte survival during differentiation by TCM. Monocytes were cultured for 6 days in TCM with 30 mg/ml RG7155 or huIgG, and survival
was analyzed by DAPI staining. Columns depicted were normalized to viable cells in the corresponding huIgG control (at least three donors; mean ± SEM;
pairwise t test; *p < 0.05, **p < 0.01). The corresponding M-CSF/GM-CSF ratio of TCM is indicated on the secondary scale (blue squares). TC-Macs were
classified as GM-CSF/CSF-1 polarized and are depicted by black bars at a CSF-1/GM-CSF ratio <50.
(legend continued on next page)
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with Various Types of Solid Malignancies and Alters
T Cell Tumor Microenvironment Composition
Macrophage reduction by RG7155 in Dt-GCT patients was fur-
ther confirmed and extended in patients with various advanced
solid tumors, using doses every 2 weeks from 200 mg up to
3000mg RG7155 in monotherapy and in combination with pacli-
taxel. Again, RG7155 treatment induced significant reduction of
CSF-1R+ cells and CD68+CD163+ macrophages in on-treatment
biopsies from tumor lesions compared to matched biopsies
taken from the same lesion prior to treatment in all patients
analyzed after 4 weeks of therapy (Figures 6A and 6B). The re-
sults from the phase 1 dose escalation trial demonstrate that
anti-CSF-1R treatment inducesmacrophage depletion in tumors
and indicate proof of mechanism in patients with various types of
malignant neoplasms. In patients who received doses of 600 mg
or higher (to ensure saturation of the target based on PK and PD
assessments), we additionally analyzed the respective T cell infil-
trate. The baseline T cell infiltrate was dominated by CD4+ T cells
and switched to a predominantly CD8+ lymphocyte infiltrate
upon therapy. This is reflected in the increased CD8/CD4 ratio
in five out of seven patients treated with RG7155 (Figure 6C),
thus mirroring observations in mouse models. Baseline infiltrate
in these patients of either CSF-1R+ cells or CD68+CD163+ TAMs
varied from 10% to 60%. However, the dramatic TAM reduction
was independent of the degree of basal macrophage infiltrate
(Figures 6B and 6C).
DISCUSSION
Here we describe a specific and potent CSF-1R targeting anti-
body, RG7155, that shows significant clinical activity in Dt-
GCT patients and reduces TAMs in tumors of patients suffering
from various cancers. In contrast to RG7155’s blocking both
ligand-dependent and -independent receptor activation, all
other blocking CSF-1R antibodies currently known to be in
phase 1 clinical development for advanced solid tumors (anti-
body AMG820, identifier NCT01444404; antibody IMC-CS4,
identifier NCT01346358) target the ligand binding domains
(Amgen, human C-FMS antigen binding proteins US2008/
073611, 2009; Imclone, antibodies against CSF-1R, US2011/
030148, 2011). Further clinical evaluation is needed to explore
whether targeting of different CSF-1R epitopes will impact effi-
cacy and safety as shown for other therapeutic antibodies tar-
geting an RTK (King and Wong 2012) and the impact of direct
versus indirect competition in settings in which the ligand con-
centration increases as much as 1,000-fold after receptor
blockade. Additional toxicities triggered by less-specific CSF-
1R small-molecule tyrosine kinase inhibitors have been dis-
cussed as another limiting factor of CSF-1R blockade in tumor
tissue (El-Gamal et al., 2013), such as imatinib, which is a(D) Macrophages were differentiated for 6 days followed by incubation with 30 mg/
was determined by DAPI staining, and data were normalized to live cells observed
(E) Constant numbers of autologous T cells were cocultured with the indicated am
beads. Proliferation was determined by CFSE dilution. Data are representative o
(F) MDA-MB231 conditioned-media-differentiated macrophages were cocultured
donors and are given as means + SD of triplicates (*p < 0.05).
See also Figure S2.weak CSF-1R inhibitor compared with its primary targets, ABL
and c-KIT (Taylor et al., 2006; Dewar et al., 2005). Imatinib mesy-
late and its more potent and better-tolerated successor, niloti-
nib, have been tested in small series of Dt-GCT patients with
only limited clinical activity (Gelderblom et al., 2013; Cassier
et al., 2012) compared to the objective clinical responses in
74% of Dt-GCT patients treated with RG7155 as described
here. The overall safety profile for RG7155 was acceptable,
with the most frequent adverse event being periorbital edema,
which mirrored the findings from the monkey study. Thus far,
none of these patients was reported to have progressive dis-
ease, with the longest follow-up being 12 months.
The molecular pathology of Dt-GCT represents a model dis-
ease for CSF-1R targeting agents, with a few aberrant cells pro-
ducing CSF-1, resulting in massive recruitment of CSF-1R
positive macrophages. Additionally, in solid malignancies such
as sarcoma or breast cancer CSF-1, overexpression by tumor
cells and an extensive CD68+ or CSF-1R+ macrophage infiltrate
are associated with poor prognosis (Espinosa et al., 2009; Kluger
et al., 2004). In solid malignancies, additional chemokines such
as MCP-1 or SDF-1 might support recruitment of monocytes
(Pollard, 2009; Murdoch et al., 2008). However, GM-CSF or
CSF-1 control TCM macrophage survival, as shown in our
in vitro studies. Since CSF-1 (unlike GM-CSF) is systemically
available (Hamilton and Achuthan 2013), we postulate that
TAMs are amenable to anti-CSF-1R therapy independently of
their recruitment mechanism. Hence, patients enrolled in the
phase 1 trial with RG7155 were not preselected for CSF-1 levels
in tumor, serum, or TAM infiltrate. Yet, in all paired tumor
biopsies, a significant reduction of CSF-1R+ TAMs upon
RG7155 therapy was detectable. Analysis into whether patients
with a stronger macrophage infiltrate benefit more from RG7155
therapy is ongoing, a question that will require treatment of a
larger patient cohort to answer. As our in vitro data show that
the presence of GM-CSF during macrophage differentiation in-
hibits RG7155 induced cell death, which has been demonstrated
previously also for a small-molecule CSF-1R inhibitor (Pyonteck
et al., 2013), it will be important to address in future clinical
studies the role of tumor-derived GM-CSF on the efficacy of
RG7155-mediated TAM depletion. In particular, pancreatic can-
cer has been described to express GM-CSF, and the role of this
growth factor in inducing immunosuppressive myeloid-derived
suppressor cells in mouse models has been reported (Bayne
et al., 2012; Dolcetti et al., 2010; Bronte et al., 2000). Even if
TAM depletion is diminished in GM-CSF-expressing tumors, in-
hibition of CSF-1R signaling can alter the polarization of macro-
phages and hence be therapeutically beneficial (Pyonteck et al.,
2013). However, tumor types to be treated with RG7155will have
to be selected carefully, taking into account that TAMs have
been also attributed good prognostic relevance, e.g., in colo-
rectal cancer (Zhang et al., 2012).ml RG7155 and/or 10 mg/ml GM-CSF-neutralizing antibody for 6 days. Survival
in huIgG control (mean ± SEM of at least four donors; **p < 0.01, ***p < 0.001).
ounts of CSF-1-differentiated macrophages and activated by anti-CD3/CD28
f five different donors and are given as means + SD of triplicates (*p < 0.05).
with T cells and activated as described above. Data are representative of two
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Figure 3. PK/PD Effects in RG7155-Treated Nonhuman Primates’ Peripheral Blood and Tissue
(A) RG7155 serum concentration-time profiles at different doses shown for the two individual animals treated per dose cohort.
(B) Increase of CSF-1 concentration in serum at the same time points as for PK analytics.
(C) Nonclassical CD14+CD16+ and classical CD14+CD16 monocytes determined by flow cytometry at baseline and after single RG7155 doses. One repre-
sentative individual dosed at 1 mg/kg (left) and 100 mg/kg (right) as the percent change from the baseline is depicted.
(D) Representative immunohistochemistry (IHC) images from one cynomolgus male animal is shown for each liver, colon, and lung from the vehicle-, 30 mg/kg
RG7155-, and 100 mg/kg RG7155-treated groups (left). Each group is represented by one male and one female treated once weekly for 2 weeks. Individual
scores for the percent area coverage of the different cell types are shown for both animals per vehicle and dosing groups tested (right).
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Figure 4. CSF-1R Inhibition Depletes TAMs and Increases Lymphocyte Infiltration into MC38 Colon Carcinomas
(A–C) Female C57BL/6Nmice were inoculated subcutaneously with 106 MC38 tumor cells and treated with 30mg/kg of either murine IgG1 control (clone MOPC-
21) or anti-CSF-1R (clone 2G2) when tumor size reached 50mm3 (day 7). Mice were treated twice (days 7 and 14 after tumor inoculation), and tumor infiltrate was
analyzed on day 16 by flow cytometry (A and B) or immunohistochemistry (C). Total tumor leukocyte and myeloid cell infiltrate were analyzed from n = 6 animals
per group (A), and lymphocyte infiltrate was analyzed from n R 3 per group (B). The graphs depict data pooled from two independent experiments for sub-
populations relative to total infiltrate (CD45+). FoxP3+ regulatory T cell and CTL infiltrate were analyzed from n = 5 per group by IHC; total cell counts were
summarized from five high power fields (HPF) each (C). The graphs in (A)–(C) showmeans ± SEM and were analyzed using an unpaired t test plus Bonferroni post
test (*p < 0.05, **p < 0.01, ***p < 0.001; n.s., not significant).
(D and E) TAM were isolated from MC38 tumors and cocultured at the ratios indicated with CFSE-labeled CD8+ T cells in the presence of CD3/CD28 stimulation
(D). T cell proliferation was analyzed in triplicates after 3 days using bead quantification of CFSElow dividing cells (shown as means + SEM). MC38 tumors were
treated continuously in weekly intervals (indicated by black arrows), and tumor growth wasmonitored every 3 to 4 days for n = 10mice per group (E). In (D) and (E),
one representative experiment is depicted as means ± SEM.
See also Figure S3.
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Targeting Tumor-Associated Macrophages in PatientsFurthermore, the Langerhans cell infiltrate in skin biopsies
from RG7155-treated patients will be analyzed since keratino-
cyte derived IL-34 was identified as their survival factor (Greter
et al., 2012). Microglia, the other macrophage population regu-
lated by neural progenitor and glial cell-derived IL-34, was not
affected in the RG7155-treated monkey brain tissue (data notshown). Currently, it is unclear whether, in the context of glio-
blastoma accompanied with an impaired blood-brain barrier, a
sufficient amount of antibody would reach the tumor. Proneural
glioblastoma (GBM) might be a promising avenue for further
development of RG7155 since this resembles a tumor type in
which inhibition of CSF-1R resulted in TAM re-education insteadCancer Cell 25, 846–859, June 16, 2014 ª2014 Elsevier Inc. 853
(legend on next page)
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Targeting Tumor-Associated Macrophages in Patientsof depletion (Pyonteck et al., 2013). Furthermore, the presence of
IL-34 has been shown to inhibit GBM cell line proliferation via its
second receptor protein-tyrosine phosphatase (Nandi et al.,
2013), which we expect to be similarly elevated upon RG7155
administration as CSF-1. Hence, the use of a CSF-1R inhibitor
in GBMmight not only indirectly effect tumor growth by reducing
TAM suppressive function and re-educating their antitumoral
state, but also directly target GBM tumor cells via IL-34.
Targeting of macrophages is a promising therapeutic
approach, considering their role in mediating resistance to can-
cer therapies. TAMs have been shown to blunt chemotherapy-
induced antitumor responses by secreting chemoprotective
factors such as MMP-9 and cathepsins (De Palma and Lewis
2013; Shree et al., 2011). A previous report of small-molecule
CSF-1R inhibitors used for macrophage depletion in PyMT
mice (DeNardo et al., 2011) described increased CD8+ T cell
levels, but only when administered in combination with chemo-
therapy. In contrast, our 2G2 antibody mediated macrophage
depletion and relatively increased CD8+ T cells and NK cells in
tumors when delivered in monotherapy. These differences might
be attributed to the dominating role of macrophages in theMC38
and MCA1 models employed for our studies or to differences in
the CSF-1R inhibitors used. The latter is more likely since an in-
crease of CD8+ T cells has been observed in PyMT using another
CSF-1R small-molecule inhibitor, BLZ945 (Strachan et al., 2013).
The immunosuppressive function of TAMs is well documented
(Cavnar et al., 2013) and was also confirmed here for the CSF-
1-dependent human in vitro-differentiated and ex vivo-isolated
murine TAMs. Most strikingly, we report that targeting of CSF-
1R results in a higher CD8/CD4 T cell ratio in tumor lesions in
the majority of the cancer patients analyzed. However, we
were unable to identify a correlation between the grade of
macrophage depletion or the severity of basal macrophage infil-
trate and the changes in the T cell composition, due to the low
number of patients analyzed. Of note, patients with a tumor
type in which macrophages have been associated with its etio-
pathology, such as mesothelioma (Yang et al., 2008), were
among those patients that showed the most pronounced
changes in lymphocyte infiltrate. Taken together, these observa-
tions provide rationale for future testing of combinations of
RG7155 with currently available immunostimulatory therapies,
such as sipuleucel-T and anti-CTLA-4 (Chen and Mellman
2013). Accordingly, an obstacle limiting the efficacy of such
immune-activating therapies may well be the presence of an
immunosuppressive myeloid infiltrate, which now can be tar-Figure 5. RG7155 Treatment Reduces Tumor Burden in Patients with D
(A) RG7155 treatment and biomarker assessment schedule. Patients were intrave
MRI assessment at baseline prior to the first RG7155 dose and on treatment at 4 w
infusions. Additionally, blood sampling was performed as indicated (solid triangl
(B) Changes in standard uptake valuemaximum (SUVmax) by FDG-PET and the su
with the baseline. Partial metabolic response in FDG-PET imaging (EORTC criteria
metabolic response. Partial response (RECIST 1.1.) was seen in five out of seven
(C) Top: FDG-PET of the left ankle of a 19-year-old Dt-GCT patient (left, pretre
6 weeks revealing significant disaggregation of the tumor.
(D) Corresponding immunohistochemistry of CD68+CD163+ TAMandCSF-1R+ ce
RG7155 treatment reduced CD68+CD163+ macrophages by 88% and CSF-1R+
(E)Whole-blood samples fromDt-GCT patientswere analyzed formonocyte subp
CD14CD16+ cells are shown as relative change from the baseline.
(F) Analysis of CSF-1R expression on monocyte subsets from healthy volunteersgeted by RG7155. While some studies have suggested an anti-
tumorigenic activity of TAM subpopulations (Weiskopf et al.,
2013; Beatty et al., 2011), targeting of the strong immunosup-
pressive function of TAMs at the cost of their potential tumorici-
dal activity is expected to be therapeutically beneficial, given that
T cells are considered to be the more powerful effector cells, due
to their capability to expand by proliferation.
In summary, we report the characterization of a specific CSF-
1R inhibitor, RG7155, that offers Dt-GCT patients a highly active
therapeutic agent. In contrast to surgical resection as the current
mainstay of treatment and investigational approaches such as
imatinib and nilotinib therapy and radiation therapy, RG7155
shows promising activity in Dt-GCT patients. In addition, we
speculate that patients with some types of solid tumors may
also benefit from the TAM-depleting effects of RG7155, espe-
cially when combined with ‘‘standard of care’’ treatments such
as chemotherapeutic drugs or immunotherapies. In this regard,
the effects of RG7155 are not limited only to reducing TAMs,
but also are likely to be manifested by increases within tumors
of other immune effector cells, as reflected by the increased
CD8/CD4 T cell ratio that we observed clinically in a broad range
of cancers.
EXPERIMENTAL PROCEDURES
X-Ray Crystallography
Prior to crystallization experiments, the Fab-ectodomain complex was degly-
cosylated with peptide-N-glycosidase. Crystallization screening was per-
formed at a concentration of 20 mg/ml in sitting-drop plates at 21C. The
largest crystals were obtained from 0.2 M lithium sulfate, 25% PEG 3350,
and 0.1 M HEPES (pH 7.5). Diffraction data were collected at a wavelength
of 1.0000 A˚ using a PILATUS 6M detector at the beamline X10SA of the Swiss
Light Source.
Data were processed with XDS (Kabsch 2010) and scaled with SADABS
(BRUKER). The structure was determined at a resolution of 2.55 A˚ by molecular
replacement with PHASER (McCoy et al., 2007) using the coordinates of an in-
house Fab fragment and of PDB entries 3EJJ and 2EC8 for Ig domains 1–4 of
the receptor. Domain 5 was directly traced into difference electron density.
Coordinates were refined by rigid-body and positional refinement using the
CCP4suite (CollaborativeComputationalProject,Number4,1994) andBUSTER
(Bricogne et al., 2011). Difference electron density was used to change amino
acids according to sequence differences by real-space refinement. Manual
rebuilding of the protein was performed using COOT (Emsley et al., 2010). The
final structure includes residues 21 to 500 of the receptor ectodomain.
Construction of Antibodies
RG7155 was generated by immunization of nuclear MRI mice with an expres-
sion vector pDisplay (Invitrogen) encoding the ECD of huCSF-1R byiffuse-type Giant Cell Tumors
nously infused biweekly and underwent tumor biopsy sampling, FDG-PET, and
eeks (FDG-PET and biopsy) and 6 weeks (MRI), i.e., after two or three RG7155
e) for assessment of PK/PD markers.
m of the largest diameter (SLD) assessed byMRI in Dt-GCT patients compared
) was observed in seven out of seven patients, two of whom had near-complete
patients at first assessment.
atment; right, on treatment). Bottom: MRI assessment of the same patient at
lls in pretreatment and on-treatment tumor biopsy from the same patient (n = 2).
cells by 91%.
opulations pretreatment and on treatment by flow cytometry. CD14+CD16 and
given as ratio of CSF-1R relative to the matching isotype.
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Figure 6. RG7155DecreasesCSF-1R+CD163+ TAM in Patientswith Various Types of Solid Tumors andAlters Intratumoral TCell Composition
(A) DetectionofCD68+CD163+TAMorCSF-1R+cells in representativepretreatment andon-treatment tumorbiopsies frompatientswithmetastatic primarypleural
mesothelioma, endometrial carcinoma, and colorectal cancer treatedwith 600 and 2,000mg (colorectal cancer) RG7155 as assessed by IHC (203magnification).
(B) The relative decrease of area coverage of CD68+CD163+ macrophages and CSF-1R+ cells is depicted as the change from the baseline, which is derived from
the pretreatment biopsy of patients treated in RG7155 monotherapy and in combination with weekly paclitaxel.
(C) Absolute numbers of CD8+ and CD4+ lymphocyte infiltrates were analyzed by IHC from the indicated patients treated with RG7155 at doses of 600 mg and
higher and are depicted as CD8/CD4 ratios of pretreatment and on-treatment biopsies with a different symbol for each individual patient. In addition, the cor-
responding CD68+CD163+ TAM and CSF-1R+ cells in pretreatment and on-treatment biopsies are shown.
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Targeting Tumor-Associated Macrophages in Patientselectroporation. Splenocyte-derived hybridomas were subcloned and
screened for inhibition of receptor-ligand interaction by ELISA and inhibition
of phosphorylation in human WT CSF-1R overexpressing NIH 3T3 cells.
RG7155 was selected as the lead candidate after extensive screening of
subcloned hybridomas in additional cell-based assays (Figures 2B, S1A, and
S1B).
2G2 was generated by immunizing hamster with mouse CSF-1R ECD pro-
tein (Wang et al., 1993). Subcloned hybridomas were screened for inhibition
of M-NFS-60 cell viability. The parental hamster antibody was chimerized to
mouse IgG1.
Monocyte-Derived Macrophages
The study was approved by the local ethics committee (Bayerische
Landesa¨rztekammer). Monocytes were enriched from whole blood by nega-
tive selection using the Rosette Sep (STEMCELL Technologies) according to
the manufacturer’s instructions. Monocytes were differentiated into macro-
phages for 6 days in RPMI plus 10% fetal bovine serum (FBS), 4 mM L-gluta-
mine with recombinant human (rhu)-CSF-1, or rhuGM-CSF for M2 or M1
macrophages, respectively. Monocytes were also treated with different ratio
of rhu-CSF-1/rhu-GM-CSF (total 100 ng/ml) for 6 days in the absence or pres-
ence of RG7155 or human IgG as a control (data not shown).
Tumor-derived macrophages were generated by culturing freshly isolated
monocytes in TCM for 6 days. These media were prepared by culturing of
tumor cell lines overnight in media containing 10% FBS followed by 3 days
in 1% FBS.
Animal Studies
Monkey
A90-day pharmacokinetic studywas conducted inmale cynomolgusmonkeys
(Maccaca fascicularis ofMauritius origin) to assessmonocyte subsets in blood,
in order to determine the CSF-1 concentration-time profiles in plasma and
serum concentration-time profiles of RG7155 after single intravenous (i.v.)
administration of 0.1, 1, 10, 30, and 100 mg/kg (n = 2 per dose group). Details
of quantification of RG7155 inmonkey serumcan be found in theSupplemental
Experimental Procedures. A 2-week toxicity studywas conducted, and IHC tis-
sue analysis of lung, liver, and colon tissue was performed after repeated i.v.
doses of 0, 30, and 100 mg/kg given once weekly for 2 weeks to male and
female cynomolgus (n = 1 per dose group and per sex). The in vivo studies
are in compliance with the Animal Welfare Act, the Guide for the Care and
Use of Laboratory Animals, and the Office of Animal Welfare. The study design
was based on the principles of the Food and Drug Administration Center for
Drug Evaluation and Research (CDER)/International Conference on Harmoni-
sation (ICH) Harmonised Tripartite Guidelines ICH-M3 and Nonclinical Safety
Studies for the Conduct of Human Clinical Trials for Pharmaceuticals (CDER,
January 2010) and was approved by the Institutional Animal Care and Use
Committee (IACUC) at our Association for Assessment and Accreditation of
Laboratory Animal Care International (AAALAC)-accredited facility.
Mouse
Female C57BL/6N mice (Charles River) were inoculated subcutaneously with
106 MC38 or injected intramuscularly with 104 MN/MCA1 tumor cells in the left
hind leg. Treatment of ten mice per group with control antibody (MOPC-21;
Bio X Cell) and anti-CSF-1R antibody 2G2 at a weekly intraperitoneal dose
of 30 mg/kg was initiated when a tumor volume of 50 mm3 was established
(for MC38) or 1 week after injection (for MN/MCA1). Tumor growth was moni-
tored by measurement of tumor size bycaliper two to three times a week. For
MN/MCA1, lung metastases were estimated 4 weeks after tumor cell injection,
as previously described (Bottazzi et al., 1986). All procedures were performed
in accordancewith the National Institutes of Health Guidelines for the Care and
Use of Laboratory Animals and European Union directives and guidelines and
were approved by the local ethics committees (for studies conducted at
Roche: Regierung von Oberbayern, Munich, Germany; for studies conducted
at the Humanitas Clinical and Research Center: Scientific Board of Humanitas
Clinical and Research Center, Milan, Italy).
Clinical Phase 1 Trial
Data are taken from an ongoing multicenter, open-label study at five study
sites in France (clinicaltrials.gov identifier NCT01494688). The study is being
conducted in accordancewith the Declaration of Helsinki, current InternationalConference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH) guidelines, and all applicable regulatory
and ethical requirements. All subjects provided written informed consent
before study-related procedures were performed. Patients with relapsed
and histologically confirmed diffuse-type giant cell tumors (formerly known
as pigmented villonodular synovitis) were enrolled, as well as patients with
solid malignancies who were not amenable to standard treatment. In the
dose escalation, RG7155 was administered every 2 weeks as an intravenous
infusion as monotherapy and in combination with a fixed weekly dose of pacli-
taxel. The study protocol was approved by the local ethics committee (Comite´
de la Protection des Personnes of Sud-Est IV) on Octover 26, 2011, and by the
French Health Products Safety Agency (ANSM) on November 10, 2011.
Metabolic-Response Assessment by FDG-PET
PET acquisition procedures were standardized across the sites, and images
were analyzed centrally. The metabolic response (MR) was assessed using
the modified guidelines of the EORTC. MRwas classified in relation to the per-
centage change from the baseline in the sum of the SUVmax for up to five
lesion values for each individual patient. Complete MR was defined as the
complete resolution of FDG uptake in all lesions, which becomes indistinguish-
able from surrounding normal tissue. Partial MR (PMR)was defined as a reduc-
tion of 25% or more in the sum of the SUVmax after two i.v. administrations of
RG7155, with no new lesions detected and no progression of those lesions not
selected for SUVmax measurement.
Flow-Cytometric Analysis
Six-week-old female C57BL/6 mice were inoculated with 106 MC38 tumor
cells and treated with either murine IgG1 or 2G2 twice (days 7 and 14 after
tumor inoculation). Leukocyte infiltrate was analyzed 2 days after the second
2G2 administration. Tumors were excised, mechanically and enzymatically
processed, and analyzed on a BD FACS Canto II (BD Biosciences). The
following antibodies (clones) were used to analyzed leukocyte infiltrate:
CD45 (30-F11), CD11b (M1/70), F4/80 (BM8), Ly6G (1A8), Ly6C (AL-21),
NK1.1 (PK136), CD4 (RM4-5), CD8 (53-6.7), and the matching isotype controls
(all fromBioLegend). Viability was determinedwith either DAPI or Zombie Aqua
(BioLegend) dyes.
TAM Suppression Assay
TAMs were enriched from single-cell suspensions of MC38 tumors after enzy-
matic digest using a two-step protocol. Single cells were stained with CD11b-
FITC (clone M1/70) and positively enriched over MACS columns by anti-FITC
beads (Miltenyi). Upon removal from the column, anti-FITC beads were de-
tached using release buffer protocol as provided by the manufacturer. Finally,
TAMs were isolated by addition of anti-Ly6G and anti-Ly6C positive selection
beads in order to remove granulocytic and monocytic cells from TAM prepa-
rations. Final cell purity was analyzed and was usually >90%. Subsequently,
TAMs were titrated in the indicated ratios to total CD3+ T cells labeled with
CFSE in U-bottom plates coated with anti-CD3, and soluble anti-CD28 was
added. Cell proliferation was determined from CFSElow cells using blank
Sphero beads as previously described after 3 days of incubation (Hoves
et al., 2006, 2011).
Statistical Analyses
Results are shown as means ±SEM or ±SD as indicated. Dose-response fits
and the calculation of the area under the curve (AUC) were performed using
the Excel plug-in XLfit. Statistical analyses were performed using GraphPad
Prism and SAS-JMP. For pairwise comparisons, the Tukey-Kramer method
was used for multiple testing correction. Individual t tests were performed
for significance assessment of the differences between treatments at different
cell states.
Further or detailed experimental procedures can be found in the Supple-
mental Experimental Procedures.
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